Prescription Pain Relief from UK-Registered Doctors

Pain is a subjective sensory and emotional experience classified clinically as acute (under 12 weeks) or chronic (persisting beyond 12 weeks).

The two categories demand different management strategies. Acute pain serves a protective function and typically responds well to short courses of analgesics.

Chronic pain involves central sensitisation, neuroplastic changes, and psychosocial amplification that make pure pharmacotherapy insufficient.

The WHO analgesic ladder, originally developed for cancer pain but widely applied, provides a rational escalation framework:

• Step 1: Non-opioid analgesics (paracetamol, NSAIDs)
• Step 2: Weak opioids (codeine, dihydrocodeine, tramadol) combined with non-opioids
• Step 3: Strong opioids (morphine, oxycodone, fentanyl) for severe or cancer-related pain

Prevalence data from the British Pain Society indicates that chronic pain affects 43% of the UK population to some degree, with 14% reporting moderately to severely disabling pain.

Musculoskeletal conditions — lower back pain, osteoarthritis, neck pain — dominate, accounting for over 60% of chronic pain presentations.

Assessment should capture:

• Pain location, character (sharp, dull, burning, shooting), and radiation pattern
• Severity on a validated numerical rating scale (0-10)
• Impact on function, sleep, mood, and daily activities
• Red flags: unexplained weight loss, night pain waking from sleep, progressive neurological deficit, fever
• Current medications and prior analgesic trials

Neuropathic pain (burning, tingling, electric-shock quality following a dermatomal pattern) requires a distinct treatment approach using amitriptyline, gabapentin, or duloxetine rather than standard analgesics.

NICE CG173 provides specific guidance for neuropathic pain pharmacotherapy.

Non-steroidal anti-inflammatory drugs (NSAIDs) remain the most prescribed class for musculoskeletal and inflammatory pain.

They inhibit cyclo-oxygenase (COX) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.

Naproxen (250-500 mg twice daily) is the preferred prescription NSAID in UK primary care.

NICE and the MHRA identify naproxen as having the lowest cardiovascular risk among non-selective NSAIDs, with a relative risk of myocardial infarction approximately 1.

1x baseline — significantly lower than diclofenac (1.4x) or ibuprofen at prescription doses (1.2x).

Ibuprofen (400 mg three times daily) is effective for mild-to-moderate pain and available over the counter at lower doses.

Prescription-strength ibuprofen provides anti-inflammatory effects comparable to naproxen but with a shorter half-life requiring more frequent dosing.

Diclofenac (50 mg three times daily) is effective but carries the highest cardiovascular risk among commonly used NSAIDs.

The MHRA restricts its use in patients with established cardiovascular disease, heart failure, or uncontrolled hypertension.

Co-codamol 30/500 combines paracetamol 500 mg with codeine phosphate 30 mg.

It sits on Step 2 of the WHO ladder and provides useful analgesia for moderate pain not controlled by NSAIDs or paracetamol alone.

Codeine is a prodrug metabolised to morphine via CYP2D6 — approximately 8% of Caucasians are poor metabolisers who gain minimal analgesic benefit.

GI protection is mandatory with NSAID prescribing:

• Co-prescribe omeprazole 20 mg or lansoprazole 15 mg for all patients over 45
• Patients with prior peptic ulcer disease, concurrent anticoagulant or corticosteroid use, or H. pylori infection face the highest GI risk
• Topical NSAIDs (diclofenac gel) offer effective local relief for osteoarthritis with minimal systemic absorption

Every analgesic carries a risk profile that must be weighed against the severity of pain and available alternatives. Prescribing without acknowledging these risks leads to avoidable harm.

NSAID gastropathy affects 15-30% of chronic users endoscopically, though only 2-4% develop clinically significant bleeding or perforation. Risk factors that multiply GI harm include:

• Age above 65 (3-fold increased risk)
• Concurrent low-dose aspirin (doubles the GI bleeding rate)
• History of peptic ulcer (6-fold risk)
• Concomitant anticoagulant use (13-fold risk)
• H. pylori infection (additive risk — test and eradicate before starting long-term NSAIDs)

Cardiovascular risk with NSAIDs is a class effect mediated by COX-2 inhibition reducing prostacyclin while sparing thromboxane.

NICE CG177 advises using the lowest effective dose for the shortest duration. Naproxen's balanced COX-1/COX-2 inhibition ratio explains its safer cardiovascular profile.

Renal toxicity from NSAIDs includes acute kidney injury (risk increases 3-fold), sodium and water retention, hyperkalaemia, and interstitial nephritis.

Patients with eGFR below 45 mL/min should avoid NSAIDs entirely. Concurrent use with ACE inhibitors and diuretics (the "triple whammy") magnifies nephrotoxicity risk substantially.

Opioid-specific concerns with co-codamol and stronger agents:

• Physical dependence develops within 5-7 days of regular use
• NICE CG173 recommends opioids for chronic non-cancer pain only after specialist review
• Respiratory depression risk increases with renal impairment, sleep apnoea, and concurrent benzodiazepines
• Codeine and dihydrocodeine cause constipation in 40-60% of users; co-prescribe a laxative from the outset

Drug interactions requiring dose adjustment or avoidance:

• NSAIDs reduce antihypertensive efficacy by 5-8 mmHg on average
• Warfarin plus NSAID: INR monitoring at least weekly during co-prescription
• SSRIs plus NSAIDs: 4-fold increase in upper GI bleeding risk
• Methotrexate: NSAIDs impair renal clearance, increasing methotrexate toxicity

Guidelines from NICE, the British Pain Society, and the Faculty of Pain Medicine consistently emphasise that chronic pain management must extend beyond tablets.

Multimodal approaches combining physical, psychological, and pharmacological strategies deliver superior outcomes to any single intervention.

Exercise therapy has the strongest evidence base for chronic musculoskeletal pain.

A Cochrane review of 264 trials found that exercise reduces pain intensity by 20-30% in osteoarthritis, chronic low back pain, and fibromyalgia.

• Aerobic exercise: 150 minutes/week at moderate intensity reduces pain sensitivity through endogenous opioid release
• Resistance training: progressive loading strengthens periarticular muscles, reducing joint stress
• Yoga and Pilates: RCTs show non-inferiority to physiotherapy-led exercise for chronic low back pain

Cognitive behavioural therapy (CBT) addresses the psychological amplification that perpetuates chronic pain.

NICE recommends CBT or acceptance and commitment therapy (ACT) as core components of chronic pain management.

A meta-analysis of 35 trials shows CBT reduces pain catastrophising by 40% and improves function scores by 25%.

TENS (transcutaneous electrical nerve stimulation) provides modest short-term relief by activating gate-control and endogenous opioid mechanisms.

Evidence quality is moderate, but TENS is safe and can reduce analgesic requirements.

Additional evidence-based approaches:

• Heat therapy for muscle spasm and chronic low back pain
• Graded motor imagery and mirror therapy for complex regional pain syndrome
• Acupuncture: NICE endorses for chronic primary pain, with modest evidence of benefit over sham
• Sleep hygiene: chronic pain disrupts sleep in 70-80% of patients, and poor sleep amplifies pain perception

Weight management plays a direct role in musculoskeletal pain.

Each kilogram of excess body weight adds 4 kg of force across the knee joint, making weight loss a potent analgesic for lower limb osteoarthritis.